Break

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Retrieved on: 
Tuesday, February 27, 2024

LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in the Phase 2 OVATION 2 Study for the localized treatment of advanced ovarian cancer.

Key Points: 
  • LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in the Phase 2 OVATION 2 Study for the localized treatment of advanced ovarian cancer.
  • We believe this combination therapy holds promise based on our preclinical animal studies, which showed strong synergies between IMNN-001 and bevacizumab.
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs. chemotherapy plus bevacizumab and IMNN-001.

O3 Mining Strengthens Presence in the Casa Berardi Trend by Consolidating the Kinebik Project

Retrieved on: 
Friday, December 22, 2023

On May 17, 2023, O3 Mining and NewOrigin announced a property sale agreement pursuant to which O3 Mining agreed to acquire (the "Kinebik Acquisition") and NewOrigin agreed to sell all of its rights, titles and interest in and to the Kinebik property located along the Casa Berardi trend in Québec (the "Kinebik Properties").

Key Points: 
  • On May 17, 2023, O3 Mining and NewOrigin announced a property sale agreement pursuant to which O3 Mining agreed to acquire (the "Kinebik Acquisition") and NewOrigin agreed to sell all of its rights, titles and interest in and to the Kinebik property located along the Casa Berardi trend in Québec (the "Kinebik Properties").
  • Please see the news release of O3 Mining dated May 17, 2023 and entitled "O3 Mining Announces Transaction to Acquire Kinebik Property from NewOrigin Gold Corp.".
  • On June 13, 2023, O3 Mining and Kinebik closed the first tranche of the Kinebik Acquisition.
  • Please see the news release of O3 Mining dated June 13, 2023 and entitled "O3 Mining Announces Closing of Kinebik Property Acquisition from NewOrigin Gold Corp.".

THE GENERAL INSURANCE AND NBA G LEAGUE ANNOUNCE SEASON TWO OF "THE BREAK, PRESENTED BY THE GENERAL"

Retrieved on: 
Monday, November 27, 2023

NASHVILLE, Tenn. and NEW YORK, Nov. 27, 2023 /PRNewswire/ -- The General Insurance, NBA G League and G League Ignite, announced today the return of "The Break, presented by The General" — a docuseries created and sponsored by The General. The second season of the docuseries, which showcases stories and personalities from across the G League with a behind-the-scenes look at players' path to the NBA, began releasing episodes monthly on Wednesday, November 22. The General is the official auto insurance partner of the NBA G League and G League Ignite.

Key Points: 
  • NASHVILLE, Tenn. and NEW YORK, Nov. 27, 2023 /PRNewswire/ -- The General Insurance, NBA G League and G League Ignite, announced today the return of "The Break, presented by The General" — a docuseries created and sponsored by The General.
  • The General is the official auto insurance partner of the NBA G League and G League Ignite.
  • "We're proud to mark another thrilling chapter in our partnership with the NBA G League and G League Ignite, allowing us to connect with basketball enthusiasts on a deeper level," said Kale Sligh, VP of marketing at The General.
  • Ball for All will tip off this season in Las Vegas on Dec. 8 when The General and the NBA G League will host children and staff members from local schools and organizations at the Santa Cruz Warriors vs. G League Ignite game.

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Inkbit™ Introduces TEPU™ 50A, a new soft-medium durometer elastomer

Retrieved on: 
Tuesday, November 7, 2023

MEDFORD, Mass., Nov. 7, 2023 /PRNewswire/ -- Inkbit™, a pioneer in advanced additive manufacturing solutions announces today, at Formnext, 2023, the availability of its new TEPU 50A elastomer. TEPU 50A is a thiol-ene polyurethane-based elastomer with a Shore 50A durometer and low compression set that offers excellent UV stability and strong chemical compatibility. TEPU 50A is the latest addition to the Inkbit Vista™ ecosystem, developed in response to customer requests for a Shore 45-55A elastomer that could accurately produce intricate detail in a wide range of geometries with excellent surface finish and elastic resilience.

Key Points: 
  • TEPU 50A is a thiol-ene polyurethane-based elastomer with a Shore 50A durometer and low compression set that offers excellent UV stability and strong chemical compatibility.
  • TEPU 50A is the second elastomer to be offered by Inkbit and follows TEPU 30A (formally known as the Vulcan Soft Elastomer 30).
  • Its suitability extends to various applications, including grommets, window and door seals, soft grippers, gaskets, and similar soft elastic components.
  • To learn more about TEPU 50A or to explore the Inkbit technology for your applications, visit inkbit3d.com/TEPU50A or contact us at [email protected] .

Inkbit™ Introduces TEPU™ 50A, a new soft-medium durometer elastomer

Retrieved on: 
Tuesday, November 7, 2023

MEDFORD, Mass., Nov. 7, 2023 /PRNewswire/ -- Inkbit™, a pioneer in advanced additive manufacturing solutions announces today, at Formnext, 2023, the availability of its new TEPU 50A elastomer. TEPU 50A is a thiol-ene polyurethane-based elastomer with a Shore 50A durometer and low compression set that offers excellent UV stability and strong chemical compatibility. TEPU 50A is the latest addition to the Inkbit Vista™ ecosystem, developed in response to customer requests for a Shore 45-55A elastomer that could accurately produce intricate detail in a wide range of geometries with excellent surface finish and elastic resilience.

Key Points: 
  • TEPU 50A is a thiol-ene polyurethane-based elastomer with a Shore 50A durometer and low compression set that offers excellent UV stability and strong chemical compatibility.
  • TEPU 50A is the second elastomer to be offered by Inkbit and follows TEPU 30A (formally known as the Vulcan Soft Elastomer 30).
  • Its suitability extends to various applications, including grommets, window and door seals, soft grippers, gaskets, and similar soft elastic components.
  • To learn more about TEPU 50A or to explore the Inkbit technology for your applications, visit inkbit3d.com/TEPU50A or contact us at [email protected] .

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

Retrieved on: 
Wednesday, October 18, 2023

LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).
  • This Phase 1/2 trial is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer.
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs. chemotherapy plus bevacizumab and IMNN-001.

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Retrieved on: 
Wednesday, October 18, 2023

The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .

Key Points: 
  • The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .
  • Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor microenvironment and in the peripheral blood.
  • Of importance, patients with recurrent HGG who had pre-existing antibodies to HSV-1 virus (66% of the patients) had a median overall survival of 14.2 months.
  • Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients.

Indigenous-authored novels: 5 great contemporary reads for young adults

Retrieved on: 
Thursday, September 28, 2023

First Voices is a Grade 11 English course that replaces works by authors like Shakespeare and Fitzgerald with texts authored by Indigenous writers like Cherie Dimaline and Richard Wagamese.

Key Points: 
  • First Voices is a Grade 11 English course that replaces works by authors like Shakespeare and Fitzgerald with texts authored by Indigenous writers like Cherie Dimaline and Richard Wagamese.
  • Over the summer, our Indigenous literatures lab, led by Haudenosaunee scholar Jennifer Brant at the Ontario Institute for Studies in Education, examined contemporary Indigenous-authored young adult texts that are well-suited for the First Voices course.

Importance of Indigenous perspectives

    • With the replacement of long-read literature comes the task of selecting texts that centre Indigenous resurgence and what Indigenous literary scholar Gerald Vizenor refers to as survivance.
    • We hope to see the stories in classrooms across the country that centre Indigenous community narratives from the voices of Indigenous Peoples.

Upholding responsibilities

    • As Cherokee author and scholar Daniel Heath Justice writes, good stories are needed that give “shape, substance and purpose” to Indigenous Peoples’ existences and shed light on how to uphold responsibilities to one another and to creation.
    • These stand in contrast to stories Justice discusses as “bad medicine,” stories often imposed from the outside, from the perspective of the colonizer.

Engaging with books

    • We encourage educators to take a strength-based perspective when discussing Indigenous literature, and also to take an anti-racist approach.
    • Anti-racist approaches acknowledge varied experiences of racism, and would help students think critically about their own lives in relationship to these books.
    • Read more:
      Why you shouldn't be afraid of critical race theory — Podcast

      Books featured here are highly acclaimed, and show narratives of Indigenous resurgence.

    • It is a story about a Métis-Anishinaabe teen and her family who are drastically impacted by a violent crime in Winnipeg.
    • As investigations uncover many unknowns, readers get meaningful insights into the realities of various characters whose lives are intricately woven together.
    • Maracle followed Ravensong with Celia’s Song, a finalist in the 2020 Neustadt International Prize for Literature.

Drilling Restarts on Globex Royalty Assets on Cadillac Break

Retrieved on: 
Monday, September 18, 2023

The property straddles the prolific gold localizing Cadillac Break.

Key Points: 
  • The property straddles the prolific gold localizing Cadillac Break.
  • Au), primarily within vertical depths between surface and 500 m of less explored areas, such as high-grade Trends #3 and #4 among others.
  • Globex retains a 2% Net Smelter Royalty on Trends #3 and #4 and others in the O’Brien East Area (Kewagama) as well as the underexplored 700 metres east of the former Kewagama Gold Mine.
  • This press release was written by Jack Stoch, Geo., President and CEO of Globex in his capacity as a Qualified Person (Q.P.)